Construction of an Innovative Nanogel and Its Applications for Achieving Chemo-Immunotherapy of Tumors

被引:0
|
作者
Wang, Sibei [1 ,2 ]
Nie, Fan [1 ,2 ]
Lin, Zhen [1 ,2 ]
Cao, Ruyu [1 ,2 ]
Xu, Jing [1 ,2 ]
Guo, Yuanqiang [1 ,2 ]
机构
[1] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
[2] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
基金
中国国家自然科学基金;
关键词
nanogels; reduction responsiveness; diosgenin; lentinan; chemotherapy; immunotherapy; DELIVERY-SYSTEM; LENTINAN; THERAPY; POLYSACCHARIDE; DRUG;
D O I
10.1021/acsami.4c13445
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Malignant tumors, also known as cancers, are a global public health problem. Nanogels are promising carriers for the delivery of anticancer medicines. Therefore, based on the unique microenvironment of tumor cells and the advantages of nanogels, a simple and economical one-pot synthesis method was designed to construct natural polysaccharide-based redox-responsive nanogels (LDD NGs). The enhanced permeability and retention (EPR) effect enriched LDD NGs in tumor cells, which then rapidly collapsed and released the natural antitumor drug diosgenin (DG) and the natural polysaccharide lentinan (LNT) via the depletion of a high level of reduced glutathione (GSH) in tumor cells, resulting in a synergistic therapeutic effect of chemotherapy and immunotherapy. In vivo antitumor experiments showed that LDD NGs could inhibit the proliferation and metastasis of the A549 lung cancer cells. Further studies indicated that LDD NGs could increase the production of ROS and induce apoptosis of A549 cells. In addition, LNT released from LDD NGs could promote the proliferation of dendritic cells, increase the production of NO, and upregulate the expressions of the costimulatory molecules CD40, CD80, CD86, and MHC-II. The construction of LDD NGs was a novel drug synthesis approach that could provide fresh ideas for the development of polysaccharide-based redox-responsive drug delivery systems.
引用
收藏
页码:59895 / 59906
页数:12
相关论文
共 43 条
  • [21] Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors
    Mei, Kuo-Ching
    Liao, Yu-Pei
    Jiang, Jinhong
    Chiang, Michelle
    Khazaieli, Mercedeh
    Liu, Xiangsheng
    Wang, Xiang
    Liu, Qi
    Chang, Chong Hyun
    Zhang, Xiao
    Li, Juan
    Ji, Ying
    Melano, Brenda
    Telesca, Donatello
    Xia, Tian
    Meng, Huan
    Nel, Andre E.
    ACS NANO, 2020, 14 (10) : 13343 - 13366
  • [22] Targeting AXL kinase with Bemcentinib to enhance Type 1 IFN response and sensitize tumors to chemo-immunotherapy
    Siraji, M. I.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S64 - S64
  • [23] Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
    Johnson, Theodore S.
    MacDonald, Tobey J.
    Pacholczyk, Rafal
    Aguilera, Dolly
    Al-Basheer, Ahmad
    Bajaj, Manish
    Bandopadhayay, Pratiti
    Berrong, Zuzana
    Bouffet, Eric
    Castellino, Robert C.
    Dorris, Kathleen
    Eaton, Bree R.
    Esiashvili, Natia
    Fangusaro, Jason R.
    Foreman, Nicholas
    Fridlyand, Diana
    Giller, Cole
    Heger, Ian M.
    Huang, Chenbin
    Kadom, Nadja
    Kennedy, Eugene P.
    Manoharan, Neevika
    Martin, William
    McDonough, Colleen
    Parker, Rebecca S.
    Ramaswamy, Vijay
    Ring, Eric
    Rojiani, Amyn
    Sadek, Ramses F.
    Satpathy, Sarthak
    Schniederjan, Matthew
    Smith, Amy
    Smith, Christopher
    Thomas, Beena E.
    Vaizer, Rachel
    Yeo, Kee Kiat
    Bhasin, Manoj K.
    Munn, David H.
    NEURO-ONCOLOGY, 2024, 26 (02) : 348 - 361
  • [24] CHEMO-IMMUNOTHERAPY OF MESOTHELIOMA: DEPLETION OF ESTABLISHED, SUPPRESSIVE CD4 T CELLS IS CRITICAL TO ACHIEVING CURES IN A MURINE MODEL
    Steer, H. J.
    Cleaver, A.
    Nowak, A.
    Robinson, B.
    Lake, R.
    THORAX, 2011, 66 : A29 - A29
  • [26] CHEMO-IMMUNOTHERAPY OF SPONTANEOUS MAMMARY-TUMORS IN C3H OUJ MICE BY CYCLOPHOSPHAMIDE AND INTERLEUKIN-2
    KAWAKAMI, Y
    GATELY, M
    DJEU, JY
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1988, 532 : 482 - 485
  • [28] Chemo-immunotherapy for advanced-stage malignancies and its impact on quality of life: Multidimensional evaluation in ten cancer patients
    Curreli, L
    Lampis, B
    Santona, MC
    Mantovani, G
    SUPPORTIVE CARE IN CANCER, 1996, 4 (06) : 462 - 464
  • [29] INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS
    Johnson, Theodore S.
    Pacholczyk, Rafal
    Aguilera, Dolly
    Berrong, Zuzana
    Castellino, Robert C.
    Chi, Susan
    Creager, Julianne
    Eaton, Bree R.
    Fangusaro, Jason R.
    Huang, Chenbin
    Hummel, Trent
    Ingerski, Lisa
    Kennedy, Eugene P.
    Ring, Eric
    Sadek, Ramses F.
    Satpathy, Sarthak
    Schniederjan, Matthew
    Thomas, Beena E.
    Yeo, Kee Kiat
    Bhasin, Manoj
    MacDonald, Tobey J.
    Munn, David H.
    NEURO-ONCOLOGY, 2023, 25
  • [30] CHEMO-IMMUNOTHERAPY OF RECENTLY DERIVED HUMAN-TUMORS IMPLANTED INTO ATHYMIC MICE - TREATMENT WITH INTERLEUKIN-2 (IL-2) AND LAK CELLS
    KEDAR, E
    LEBENDIKER, Z
    SHOUVAL, D
    WEISS, DW
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 404 - 404